Monographs: Dosage forms: Specific monographs: Pyrimethamine tablets (Pyrimethamini compressi)2024-01
Category. Antimalarial. Storage. Pyrimethamine tablets should be kept in a well-closed container, protected from light. Additional information. Strengths in the current WHO Model List of Essential Medicines (EML): 25 mg. Strength in the current WHO EML for children: 25 mg. Requirements Comply with the monograph for Tablets. Definition. Pyrimethamine tablets contain not less than 90.0% and not more than 110.0% of the labelled amount of Pyrimethamine (C12H13ClN4). Identity tests.
Dissolution. Carry out the test described under 5.5 Dissolution test for solid oral dosage forms, using as the dissolution medium 900 mL of hydrochloric acid (~3.65 g/L) TS and rotating the paddle at 50 revolutions per minute. At 45 minutes, withdraw a sample of 10 mL of the medium through an in-line filter. Measure the absorbance (1.6) of a 1-cm layer of the filtered sample at the maximum at about 272 nm, using the dissolution medium as the blank. For each of the tablets tested, calculate the total amount of pyrimethamine (C12H13ClN4) in the medium using the absorptivity value of 31.6 for pyrimethamine ( Related substances. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using the conditions given under "Assay". Use solution (1) as described under "Assay". Prepare the following additional solutions. For solution (2), dilute 10.0 mL of solution (1) to 100.0 mL with mobile phase. Dilute 1.0 mL of this solution to 100.0 mL with mobile phase. For solution (3), prepare 20 mL of a 1.25 mg/mL solution of pyrimethamine RS in sulfuric acid (~570 g/L) TS in a 25 mL conical flask. Heat the solution on a hotplate until it boils. Continue to heat to reduce the volume to about half of its original volume. The final solution should be clear with a light tinge of yellow. Cool and dilute 1 volume of this solution to 10 volumes with mobile phase. Inject 30 μL of solution (3). Record the chromatogram for about 2.5 times the retention time of pyrimethamine (retention time about 12 minutes). The impurities are eluted at the following relative retention with reference to pyrimethamine: impurity A about 0.35; impurity B about 0.45; impurity C about 0.64; impurity D about 0.15; impurity E about 0.42; impurity F about 0.52 and impurity G about 2.28. The test is not valid unless in the chromatogram obtained with solution (3) the resolution between impurities A and B is at least 3.0. Inject alternately 30 μL of solutions (1) and (2). Use the chromatogram obtained with solution (3) to identify the peaks due to the impurities A, B and C. In the chromatogram obtained with solution (1):
Assay. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using a stainless steel column (10 cm x 4.6 mm) packed with end-capped particles of silica gel, the surface of which has been modified with chemically-bonded octadecylsilyl groups (3.5 µm). Prepare an ammonia solution by adding 10.0 mL of ammonia (~260 g/L) TS to 150 mL of water R, mix and dilute to 200.0 mL with water R. Prepare the ammonium bicarbonate buffer pH 9.3 by dissolving 0.8 g of ammonium bicarbonate R in 1500 mL of water R, adjust the pH to 9.3 by adding the ammonia solution (about 25 mL), mix and dilute to 2000.0 mL with water R. As the mobile phase, use a mixture of 55 volumes of ammonium bicarbonate buffer pH 9.3 and 45 volumes of methanol R. Operate with a flow rate of 1.5 mL per minute. As a detector, use an ultraviolet spectrophotometer set at a wavelength of 280 nm. For identity test B.2 use a diode array detector in the range of 210 nm to 400 nm. Maintain the column temperature at 35 °C. Prepare as a solvent solution a mixture of 50 volumes of acetic acid (~ 10 g/L) TS and 50 volumes of methanol R. Prepare the following solutions. For solution (1), weigh and powder 20 tablets. Transfer a quantity of the powdered tablets, containing about 125.0 mg of pyrimethamine into a 100 mL volumetric flask. Add approximately 75 mL of the solvent solution and sonicate for about 10 minutes. Dilute to volume with the solvent solution, mix and filter. Dilute 5.0 mL of the filtrate to 50.0 mL with mobile phase. For solution (2), dissolve 12.5 mg pyrimethamine RS in 20 mL of the solvent solution, sonicate for 10 minutes and dilute to 100.0 mL with mobile phase. Inject 30 µL of solutions (1) and (2). Measure the areas of the peaks corresponding to pyrimethamine obtained in the chromatograms from solutions (1) and (2) and calculate the percentage content of C12H13ClN4 in the tablets, using the declared content of C12H13ClN4 in pyrimethamine RS. Impurities. The related substances limited by the requirements of this monograph include those listed in the monograph on Pyrimethamine.
|